ArticleCanadian journal of kidney health and disease2014
A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada.
Article in Canadian journal of kidney health and disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Retrospective Study on the Influencing Factors and Prediction of Hospitalization Expenses for Chronic Renal Failure in China Based on Random Forest and LASSO Regression.Frontiers in public health · 2021Article
- Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review.Canadian journal of kidney health and disease · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Europe, epoetin subsequent entry biologics (SEBs) have been in use since 2007. Canadian patents of erythropoietin stimulating agents are expiring in 2014, therefore it is predicted that epoetin SEBs will penetrate the Canadian market in the near future.
objectiveTo estimate the economic impact and costs offsets associated with the uptake and use of one or more epoetin SEBs in Canada for the treatment of anemia in chronic kidney disease.
designA Canada-wide epidemiological-based budget impact analysis was conducted to estimate cost outcomes under two scenarios: with and without the availability of epoetin SEB.
settingThe analysis was conducted from the perspective of the Canadian healthcare payer, over a 5-year time horizon from 2015 to 2019. PATIENTS: Patients included in the model were those with chronic kidney disease stages 3 to 5, who have renal anemia and require treatment with erythropoietin stimulating agents.
methodsOnly direct medical costs pertaining to drug acquisition of currently available erythropoietin stimulating agents in Canada were incorporated in the model. Cost of epoetin SEBs, market shares, uptake rates, and other model inputs were estimated from published sources or databases. No discounting of future costs was applied.
resultsBased on our analysis, under market phenomena similar to those seen in the Europe and without considering potential switching from originator epoetin to epoetin SEB, we could expect that Canadian adoption of epoetin SEBs could result in $35 million (2013 CAD, year 1) to $50 million (year 5) cost savings annually, with cumulative savings of $221 million after 5 years. In one-way sensitivity analyses, model variables with substantial impact on cost savings were the prevalence of chronic kidney disease and epoetin SEB uptake rates. LIMITATIONS: We did not take into account costs associated with overhead, administration, or adverse events.
conclusionThe advent of SEBs represents an opportunity to relieve financial pressure in our healthcare system. Under the assumption that the efficacy and safety of epoetin SEBs are non-inferior to originator products, we have shown that the adoption of epoetin SEBs can lead to cost savings for the Canadian payer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.